Promoting Smoking Cessation and Preventing Relapse to Tobacco Use following a smokefree mental health in-patient stay (SCEPTRE feasibility study): a multi-centre randomised controlled feasibility study protocol

Petal Petersen Williams,Lisa Huddlestone,Emily Shoesmith,Samantha Brady,Alex Mitchell,Victoria Exley,Fraser Wiggins,Lesley Sinclair,Jodi Pervin,Michelle Horspool,Moira Leahy,Claire Paul,Lesley Colley,Lion Shahab,Jude Watson,Catherine Hewitt,Simon Hough,John Britton,Tim Coleman,Simon Gilbody,Steve Parrott,Paul Galdas,Gregor Russell,Peter Coventry,Elena Ratschen
DOI: https://doi.org/10.1101/2024.10.31.24316412
2024-11-02
Abstract:Introduction Thousands of patients with mental illness are admitted to acute adult mental health wards every year in England, where local guidance recommends that all mental health settings be entirely smokefree. Mental health trusts presently invest substantial effort and resources to implement smokefree policies and to deliver tobacco dependence treatment to patients. Providing adequate support can help smokers remain abstinent or quit smoking during their smokefree inpatient stay and beyond. At present, little is known about how best to support patients to prevent their return to pre-admission smoking behaviours after discharge from a smokefree mental health inpatient stay. We have developed an intervention which includes targeted resources to support smoking-related behaviour change in patients following discharge from a smoke-free mental health setting. The aim of this trial is to determine the feasibility of a large-scale clinical trial to test the effectiveness and cost-effectiveness of the SCEPTRE intervention, compared with usual care. Methods and Analysis This feasibility study will be an individually randomised, controlled trial in eight National Health Service (NHS) mental health trusts recruiting adults (18 years and older) admitted to an acute adult mental health inpatient setting who are tobacco smokers on admission, or at any point during their inpatient stay. Consenting participants will be randomised to receive a 12-week intervention consisting of components aimed at promoting or maintaining positive smoking-related behaviour change following discharge from a smoke-free mental health inpatient setting or usual care. Data will be collected at baseline, 3-months and a second timepoint between 4-6 months post-randomisation. With 64 participants (32 in each group) the trial will allow a participation rate of 15% and completion rate of 80% to be estimated within a 95% confidence interval of +/-3% and +/-10% respectively. The analysis will be descriptive and follow a prespecified plan. Ethics and Dissemination Ethics approval was obtained from the North West - Greater Manchester West Research Ethics Committee. We will share results widely through local, national and international academic, clinical and Patient and Public Involvement (PPI) networks. The results will be disseminated through conference presentations, peer-reviewed journals and will be published on the trial website: https://sceptreresearch.com/.
What problem does this paper attempt to address?